Dapivirine News and Research

RSS

Dapivirine is an experimental non-nucleoside reverse transcriptase inhibitor. A gel formulation of dapivirine is now being investigated as a vaginal microbicide.

Researchers present more findings for microbicides, prep at M2010 conference

Researchers on Monday at the International Microbicides Conference in Pittsburgh continued to present data on HIV prevention research, Reuters reports. The news service outlines several prevention methods being researched, including an intravaginal ring that over time releases two antiretrovirals - dapivirine and maraviroc - for up to a month, and a vaginal tablet that time-releases the antiretrovirals dapivirine and DS003 for up to 12 hours.

26 May 2010

Research on new types of anti-HIV drugs presented at International Microbicides Conference

Researchers testing a vaginal microbicide based on a new type of anti-HIV drug found it provided monkeys significant protection against infection with a virus similar to HIV, according to a study reported at the International Microbicides Conference in Pittsburgh today.

24 May 2010

International initiative seeks to reduce heterosexual HIV transmission

Los Angeles Biomedical Research Institute has received a $350,000 grant to study the safety of a gel designed to reduce the heterosexual transmission of HIV from the International Partnership for Microbicides, a nonprofit global initiative to develop products to reduce HIV transmission, and the U.S. Agency for International Development, the Institute announced today.

28 Apr 2010

New vaginal ring designed to prevent sexual transmission of HIV

Researchers from Weill Cornell Medical College have published results showing that a new contraceptive device may also effectively block the transmission of the HIV virus. Findings show that the device prevents infection by the HIV virus in laboratory testing. The promising results are published in the most recent issue of the journal AIDS.

19 May 2009

Vaginal rings provide new HIV protection for women

Vaginal rings, similar to those used for contraception and hormone replacement therapy, could protect women from sexually-transmitted HIV, according to research presented at the British Pharmaceutical Conference (BPC) in Manchester.

8 Sep 2008

Relatively difficult for the AIDS virus to develop resistance to the drug, tenofovir, or the DAPY (diarylpyrimidine) family of compounds

HIV is a moving target, unpredictably changing direction to elude anti-AIDS drugs, but researchers at Rutgers are clearly on the track of solutions to combat HIV drug resistance.

29 Jun 2004